William Duckworth, M.D Get more information ., Carlos Abraira, M.D., Thomas Moritz, M.S., Domenic Reda, Ph.D., Nicholas Emanuele, M.D., Peter D. Reaven, M.D., Franklin J. Zieve, M.D., Ph.D., Jennifer Marks, M.D., Stephen N. Davis, M.D., Rodney Hayward, M.D., Stuart R. Warren, J.D., Pharm.D., Steven Goldman, M.D., Madeline McCarren, Ph.D., M.P.H., Mary Ellen Vitek, William G. Henderson, Ph.D., and Grant D. Huang, M.P.H., Ph.D. For the VADT Investigators: Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes Several trials have shown that intensive glucose control in patients with type 2 diabetes mellitus reduces the progression of microvascular disease,1,2 but the influence on macrovascular complications remains uncertain.

It disproportionately impacts the developing Hispanic population, where the prevalence of type 2 diabetes is two to three times higher than in non-Hispanic whites. Obesity often precedes the starting point of type 2 diabetes, which can make people more susceptible to a host of other health problems, including cardiovascular disease, kidney disease, and blindness. Type 2 diabetes makes up about more than 90 % of diabetes worldwide, with scientists estimating that you will have 220 million cases worldwide by 2010. Then changes in lifestyle alone may not assist you to. That’s why we need to discover the genes included and the DNA variants that influence those genes’ function. That will give pharmaceutical companies the given information they need to develop new medicines to fight this growing health problem.